Compare Adaptive Biotechnologies Corp (ADPT) vs Constellation Energy Corporation (CEG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Constellation Energy Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $24.96 (market cap $4.04B), while Constellation Energy Corporation trades at $279.75 (market cap $98.63B). The key difference: Constellation Energy Corporation is far larger — about 24.4× Adaptive Biotechnologies Corp's market cap, and Constellation Energy Corporation pays a 0.61% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CEG | |
|---|---|---|
Market Cap | $4.04B | $98.63B |
Sector | Health | Energy |
52-Week High | $25.45 | $403.95 |
52-Week Low | $12.30 | $236.50 |
Enterprise Value | $4.10B | $122.63B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Constellation Energy (CEG) is trading at $281.84, up 4.22% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS of $2.55 beating expectations by 11.4%, and raised 2026 guidance. Recent news highlights nuclear power contracts with major tech companies driving growth. Technical indicators show bullish momentum with support at $277 and resistance at $282.
CEG presents a compelling investment case with strong earnings momentum, AI-driven power demand tailwinds, and 70% analyst buy ratings. Risks include execution of nuclear capacity expansion and potential regulatory changes. The consensus price target of $332.13 suggests 18% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →
